ArticleCancer discovery2020
The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies.
Abstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- FFPE-CUTAC: A Single Assay, Multiple Layers.bioRxiv : the preprint server for biology · 2026Article
- A proteogenomic RNA processing mechanism drives sex differences in meningioma.Research square · 2026Article
- Neural crest gene regulatory networks as drivers of development, diversification and disease.Nature reviews. Molecular cell biology · 2026Review
- Subgroup of meningiomas involving FOS and FOSB gene fusions.Nature communications · 2025Article
- An evolutionarily conserved constellation of functional cis-elements programs the virus-responsive fate of the human (epi)genome.Nucleic acids research · 2025Article
- RNA splicing as a biomarker and phenotypic driver of meningioma DNA-methylation groups.Neuro-oncology · 2024Article
- Upregulation of hsa-miR-141-3p promotes uterine cervical carcinoma progression via targeting dual-specificity protein phosphatase 1.Functional & integrative genomics · 2024Article
- Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcome.Cell genomics · 2024Article
- Nuclear respiratory factor 1 regulates super enhancer-controlled SPIDR to protect hepatocellular carcinoma cells from oxidative stress.BMC gastroenterology · 2024Article
- Meningioma: current updates on genetics, classification, and mouse modeling.Upsala journal of medical sciences · 2024Review
- Meningiomas in patients with neurofibromatosis type 2 predominantly comprise 'immunogenic subtype' tumours characterised by macrophage infiltration.Acta neuropathologica communications · 2023Article
- Comprehensive analysis of mJournal of translational medicine · 2023Article
- Etiology of super-enhancer reprogramming and activation in cancer.Epigenetics & chromatin · 2023Review
- Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features.Neuro-oncology · 2023Article
- Signaling pathways in brain tumors and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- The Epigenetic Landscape of Meningiomas.Advances in experimental medicine and biology · 2023Article
- Case report and literature review: exploration of molecular therapeutic targets in recurrent malignant meningioma through comprehensive genetic analysis with Todai OncoPanel.Frontiers in neurology · 2023Article
- Radiotherapy for meningiomas.Journal of neuro-oncology · 2022Review
- Typical Enhancers, Super-Enhancers, and Cancers.Cancers · 2022Review
- Intratumor and informatic heterogeneity influence meningioma molecular classification.Acta neuropathologica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Briana C PragerDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Harish N VasudevanDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Deobrat DixitDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Jean A BernatchezSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California.ORCID https://orcid.org/0000-0002-8309-1627
Qiulian WuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Lisa C WallaceDepartment of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio.
Shruti BhargavaDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Derrick LeeDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Bradley H KingDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Andrew R MortonCase Western Reserve University Medical Scientist Training Program, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Ryan C GimpleDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.ORCID https://orcid.org/0000-0002-7189-3243
Melike PekmezciDepartment of Pathology, University of California, San Francisco, San Francisco, California.ORCID https://orcid.org/0000-0003-2548-8359
Zhe ZhuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.ORCID https://orcid.org/0000-0002-5385-948X
Jair L Siqueira-NetoSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California.
Xiuxing WangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.ORCID https://orcid.org/0000-0002-5993-9368
Qi XieDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Clark ChenDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota.
Gene H BarnettDepartment of Neurosurgery, Cleveland Clinic, Cleveland, Ohio.ORCID https://orcid.org/0000-0001-8678-4106
Michael A VogelbaumDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota.
Stephen C MackBaylor College of Medicine, Houston, Texas.ORCID https://orcid.org/0000-0001-9620-4742
Lukas ChavezDepartment of Medicine, University of California, San Diego, San Diego, California.
Arie PerryDepartment of Pathology, University of California, San Francisco, San Francisco, California.ORCID https://orcid.org/0000-0002-8300-7261
David R RaleighDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California. David.Raleigh@ucsf.edu drjeremyrich@gmail.com.
Jeremy N RichDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California. David.Raleigh@ucsf.edu drjeremyrich@gmail.com.
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MDynamic Complexity of Brain Tumor Stem Cells (R35CA197718)R35CA197718 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2015 to 2021
$6.4MNRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9MTargeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)R01CA238662 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAY, STEVE A, RICH, JEREMY N · 2020 to 2024
$2.8MUnderstanding druggable drivers of meningioma tumorigenesisR01CA262311 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2021 to 2025
$2.7MDevelopment of Quantitative Deuterium MRS Imaging for Human Brain Tumor Application at Ultrahigh FieldR01CA240953 · NCI · UNIVERSITY OF MINNESOTA · PI CHEN, WEI, LIANG, ZHI-PEI · 2019 to 2025
$2.7MTargeting Ferritin in GlioblastomaR01CA169117 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI BAO, SHIDENG, CONNOR, JAMES ROBERT · 2013 to 2017
$2.7MMetabolism Informs Intertumoral & Intratumoral HeterogeneityR01NS087913 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NAKANO, ICHIRO, RICH, JEREMY N · 2014 to 2018
$2.0MTargeting Brain Tumor Stem Cells Through Novel Therapeutic CombinationsR01CA154130 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI RICH, JEREMY N · 2010 to 2014
$1.9MDual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434)R01NS103434 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2017 to 2021
$1.7MTargeting Mechanisms of Acquired Temozolomide Resistance in GlioblastomaR01NS097649 · NINDS · UNIVERSITY OF MINNESOTA · PI CHEN, CLARK CHIN-CHUNG · 2016 to 2021
$1.7MEnergy Stress in Brain Tumor Initiating Stem CellsR01NS089272 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICH, JEREMY N · 2014 to 2018
$1.7MNCATS NIH HHS TL1 TR002549NCI NIH HHS F30 CA217065NCI NIH HHS F30 CA217066NCI NIH HHS K08 CA212279NCI NIH HHS R01 CA154130NCI NIH HHS R01 CA169117NCI NIH HHS R01 CA171652NCI NIH HHS R01 CA238662NCI NIH HHS R01 CA240953NCI NIH HHS R01 CA262311NCI NIH HHS R35 CA197718NIDA NIH HHS R44 DA045460NIGMS NIH HHS R44 GM128223NIGMS NIH HHS T32 GM007250NINDS NIH HHS R01 NS087913NINDS NIH HHS R01 NS089272NINDS NIH HHS R01 NS097649NINDS NIH HHS R01 NS103434
Abstract
Meningiomas are the most common primary intracranial tumor with current classification offering limited therapeutic guidance. Here, we interrogated meningioma enhancer landscapes from 33 tumors to stratify patients based upon prognosis and identify novel meningioma-specific dependencies. Enhancers robustly stratified meningiomas into three biologically distinct groups (adipogenesis/cholesterol, mesodermal, and neural crest) distinguished by distinct hormonal lineage transcriptional regulators. Meningioma landscapes clustered with intrinsic brain tumors and hormonally responsive systemic cancers with meningioma subgroups, reflecting progesterone or androgen hormonal signaling. Enhancer classification identified a subset of tumors with poor prognosis, irrespective of histologic grading. Superenhancer signatures predicted drug dependencies with superior
Indexed as
EpigenomicsHumansMeningiomaPrognosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.